Last reviewed · How we verify

Cold autoimmune hemolytic anemia — Treatment Landscape & Competitive Intelligence

Cold autoimmune hemolytic anemia (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Cold autoimmune hemolytic anemia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Enjaymo SUTIMLIMAB Bioverativ Therapeutics Inc Classical Complement Pathway Inhibitor [EPC] Complement C1s subcomponent 2022-01-01
ENJAYMO SUTIMLIMAB-JOME RECORDATI RARE DISEASES, INC. Classical Complement Pathway Inhibitor [EPC] Complement C1s subcomponent

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Bioverativ Therapeutics Inc · 1 drug in Cold autoimmune hemolytic anemia
  2. RECORDATI RARE DISEASES, INC. · 1 drug in Cold autoimmune hemolytic anemia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Cold autoimmune hemolytic anemia:

Cite this brief

Drug Landscape (2026). Cold autoimmune hemolytic anemia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/cold-autoimmune-hemolytic-anemia. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing